criteria were: (a) articles with full-text availability (n = 64) and (b) studies that included, at least, one control group without RAS (n = 47). The exclusion criteria were: (a) studies without clinical data (n = 12) and (b) studies with irrelevant or nonusable data (n = 16). After the application of these criteria, 19 articles were analyzed in this meta-analysis [ Figure 1 ].
Statistical analysis
The meta-analysis was performed with the RevMan 5.3 program (The Cochrane Collaboration, Oxford, UK). For dichotomous variables, the Mantel-Haenszel Chi-square odds ratio (OR) with 95% confidence interval (CI) was used. For continuous variables, the inverse of the variance for the mean difference (MD) with 95% CI was used. Heterogeneity was determined according to the Higgins statistic (I 2 ). The random-effects model was applied in cases of high heterogeneity. P < 0.05 was considered statistically significant. Table 1 presents the main descriptive characteristics of the 19 studies considered in this meta-analysis. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] The different hematological parameters assessed in patients with RAS and controls are shown in Table 2 .
Results
Regarding the iron, 11 studies [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] compared the presence of low iron levels (<50 μg/dL) in RAS patients versus control subjects without the disease. RAS patients were 6.67 times more likely to have low iron levels, with highly significant statistical differences (OR = 6.67, 95% CI: 2.37-18.77, P < 0.001). Six studies [8, [11] [12] [13] 15, 16] analyzed the iron concentrations both in the RAS patients group and control group, observing lower iron concentrations of 11.75 μg/dL on average in RAS patients with respect to controls. After the statistical analysis, a highly significant association was observed (MD = −11.75, 95% CI: −15.76-−7.74, P < 0.001).
Fourteen studies [5] [6] [7] [8] [9] [11] [12] [13] [14] [15] [17] [18] [19] [20] examined the presence of low levels of Vitamin B 12 (<200 pg/mL) in patients with RAS with respect to controls subjects. RAS patients were 3.99-fold more likely to have low levels of Vitamin B 12 , with a highly significant statistical relationship (OR = 3.99, 95% CI: 2.43-6.53, P < 0.001). Another seven studies [8, [11] [12] [13] 15, 16, 21] examined Vitamin B 12 concentrations in both groups, RAS patients and controls. Vitamin B 12 concentrations in RAS patients were lower in 31.35 pg/mL on average compared to controls. Statistical analysis showed significant differences (MD = −31.35, 95% CI: −55.75-−6.94, P = 0.01).
Fourteen studies [5, [7] [8] [9] 11, [13] [14] [15] [17] [18] [19] [20] 22, 23] considered the low levels of folic acid (<6 ng/mL) in RAS patients and controls. Patients with RAS were 4.98 times more likely to present low levels of folic acid respect to controls, with a highly significant statistical association (OR = 4.98, 95% CI: 2.67-9.30. P < 0.001). Moreover, six studies [8, 11, 13, 15, 16, 21] compared folic acid concentrations in both groups, finding folic acid concentrations lower in 0.95 ng/mL on average in RAS patients. After the statistical analysis, a very significant relationship was found (MD = −0.95, 95% CI: −1.53-−0.38, P < 0.01).
Six studies [8, 12, 13, 15, 18, 19] assessed the low hemoglobin levels (<14 g/dL) in patients with RAS and controls without the disease. RAS patients were 17.30-fold more likely to have low hemoglobin levels, with very significant statistical differences (OR = 17.30, 95% CI: 2.27-131.79, P < 0.01). Respect to the mean hemoglobin concentrations in both study populations, [8, 13, 15, 16] RAS patients had lower hemoglobin concentrations in 0.85 g/dL on average compared to controls. The statistical analysis showed a highly significant relationship (MD = −0.85, 95% CI: −1.21-−0.49, P < 0.001).
Eight studies [7, 9, 11, [17] [18] [19] [20] 23] analyzed the levels of serum ferritin, finding lower levels (<15 ng/mL) in patients with RAS. These patients were 2.86 times more likely to have low ferritin levels than controls without the disease. The statistical association was highly significant (OR = 2.86, 95% CI: 1.97-4.14, P < 0.001). Three studies [11, 16, 23] investigated mean concentrations of serum ferritin in RAS patients and controls, although no statistically significant differences were found (MD = −14.57, 95% CI: −56.54-27.39, P = 0.50).
Finally, four studies [8, 13, 15, 21] investigated blood homocysteine in RAS patients versus controls. About 8.6% of RAS patients (61/708) and 1.3% of controls (13/970) had high homocysteine levels (>10.4 μmol/L). Patients with RAS were 7.22-fold more likely to have high homocysteine levels, with a highly significant statistical relationship (OR = 7.22, 95% CI: 3.90-13.38, P < 0.001). In contrast, when homocysteine concentrations were compared in both population groups, there were no statistically significant differences (MD = −0.02, 95% CI: −0.11-0.08, P = 0.74).
dIscussIon
In the present meta-analysis on the possible influence of different hematological parameters on RAS, data from 19 studies were included.
In this study, RAS patients had 6.67 times more likely than controls to have low iron levels (<50 μg/dL) with statistically [20] 1988 UK 69 RAS patients 75 controls Folic acid, Vitamin B 12 , and ferritin Hematinic deficiencies: 6.0% RAS patients 3.2% controls Gönül et al. [21] 2009 Turkey 47 RAS patients 69 controls Folic acid, Vitamin B 12 , and homocysteine No significant differences between two groups Thongprasom et al. [22] 2002 Thailand 23 RAS patients 19 controls Folic acid, Vitamin B 12 , and hemoglobin Hematinic deficiencies: 21.7% RAS patients 0% controls Challacombe et al. [23] 1983 UK 105 RAS patients 78 controls Ferritin Hematinic deficiency: 8.0% RAS patients 3.0% controls RAS=Recurrent aphthous stomatitis; Controls=Individuals without RAS significant differences (P < 0.001). The 11 studies [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] that considered this parameter also found low iron levels in RAS patients. Similarly, patients with RAS had significantly lower iron concentrations (11.75 μg/dL lower on average) compared to controls (P < 0.001). Of the six studies [8, [11] [12] [13] 15, 16] that analyzed these iron mean concentrations, only one of them [11] found lower iron concentrations in the controls, although without a significant relationship. Iron deficiency is responsible for anemia in which the decrease in the number of erythrocytes results in less oxygen transport to tissues, including the oral mucosa. This lack of oxygen affects the differentiation and maturation of the epithelial cells causing the atrophy of the oral mucosa. This atrophy increases tissue susceptibility favoring antigenic exposure and the development of a cytotoxic immunological response that could lead to RAS. [13] With respect to Vitamin B 12 , in the present study, RAS patients had 3.99-fold more likely of having low levels of this vitamin compared to controls. After the statistical analysis, highly significant differences were found (P < 0.001). Thirteen studies [6] [7] [8] [9] [11] [12] [13] [14] [15] [17] [18] [19] [20] coincided in finding low Vitamin B 12 levels (<200 pg/mL) in patients with RAS; meanwhile, a single study observed low levels in the controls. [5] Similarly, RAS patients had Vitamin B 12 concentrations lower in 31.35 pg/mL on average in contrast to those in controls with a statistically significant relationship (P = 0.01). Only one of the seven studies [8, [11] [12] [13] 15, 16, 21] that evaluated these concentrations found higher Vitamin B 12 concentrations in patients with RAS. [21] Vitamin B 12 deficiency, either separately or in combination with other deficiencies of the Vitamin B complex, can be a possible precipitating factor for RAS. Vitamin B 12 plays an important role in the synthesis of DNA and cell division of epithelial cells, and its deficiency may result in atrophy of the oral epithelium. In addition, according to some studies, replacement therapy with Vitamin B 12 produces a clinical improvement in RAS patients, reducing the frequency, and severity of oral aphthous ulcers. [13] The possible relationship between folic acid and RAS was also investigated. A greater number of RAS patients had low levels (<6 ng/mL) of folic acid, in line with findings of 14 studies. [5, [7] [8] [9] 11, [13] [14] [15] [17] [18] [19] [20] 22, 23] In fact, RAS patients were 4.98 times more likely than controls to have low levels of folic acid with a highly significant statistical association (P < 0.001).
Six studies [8, 11, 13, 15, 16, 21] also investigated folic acid concentrations in patients with RAS and in controls. Patients showed lower folic acid concentrations (0.95 ng/mL lower on average) compared to controls with very significant statistical differences (P = 0.001). Only one study [16] did not find lower folic acid concentrations in RAS patients, although these results could be conditioned by the characteristics of the population included in that study. Folic acid deficiency also induces oral mucosa atrophy and increases the inflammation, situations that favor the appearance of oral aphthae. [13] As in the case of Vitamin B 12 , folic acid replacement therapy has shown an improvement in patients with RAS. [18] When analyzing hemoglobin, RAS patients had 17.30 times more likely of having low hemoglobin levels (<14 g/dL) compared with controls. After the statistical analysis, a very significant relationship was observed (P < 0.01). Six studies [8, 12, 13, 15, 18, 19] coincided in finding low levels of hemoglobin in RAS patients. Likewise, lower hemoglobin concentrations in 0.85 g/dL on average were found in patients with RAS, with a highly significant statistical association (P < 0.001) in consonance with the results of three studies. [8, 13, 15] The lack of hemoglobin reduces the capacity of the blood to transport oxygen to the oral tissues, inducing epithelial atrophy that increases the risk of developing RAS lesions. [13] Of the eight studies [7, 9, 11, [17] [18] [19] [20] 23] that investigated the ferritin levels, all of them found low ferritin levels (<15 ng/mL) in RAS patients with respect to the control subjects. Patients with RAS were 2.86-fold more likely to have low ferritin levels, with a highly significant statistical relationship (P < 0.001). Nevertheless, when ferritin concentrations were analyzed both RAS patients and controls, no statistically significant differences were found (P = 0.50).
There is a direct relationship between iron and ferritin levels, the decrease of ferritin has the same biological effect on tissues as iron deficiency. [19] In RAS patients, it seems that other factors such as age or sex influence ferritin levels. Hence, serum ferritin deficiency is more common in young women with RAS. [17] Finally, four studies [8, 13, 15, 21] assessed the possible influence of homocysteine on RAS. Patients with RAS had 7.22-fold more likely to have high homocysteine levels (>10.4 μmol/L) compared to controls, with a highly significant statistical association (P < 0.001). However, in the case of blood homocysteine concentrations, no statistically significant differences (P = 0.74) were observed between RAS patients and controls. The increase in blood homocysteine levels can cause oxidative cell stress and endothelial damage. [13] In patients with RAS, Vitamin B 12 deficiency increases the levels of homocysteine that induces the thrombosis of the blood capillaries which supply the oral tissues, favoring the breakdown of the epithelial integrity, and the development of aphthous ulcers. [8] The high heterogeneity of some studies considered in this meta-analysis and the methodological differences among the different studies could be a potential source of bias, compelling to interpret the findings with caution.
conclusIon
In this meta-analysis, RAS patients were more likely to have significantly lower levels of hemoglobin (OR: 17.30 and MD: −0.85 g/dL), iron (OR: 6.67 and MD: −11.75 μg/dL), folic acid (OR: 4.98 and MD: −0.95 ng/mL), Vitamin B 12 (OR: 3.99 and MD: −31.35 pg/mL), and ferritin (OR: 2.86). In contrast, these patients had higher homocysteine values (OR: 7.22).
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